Parenteral Ascorbic Acid Repletion in TransplantatIon
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A single-center, randomized, double-blinded placebo-controlled trial is proposed to
investigate administration of supraphysiologic doses of ascorbic acid (vitamin C, AA) to
patients undergoing liver transplantation. Participants randomized to the intervention group
will receive intravenous (IV) AA 1500 mg every 6 hours for 48 hours. Participants randomized
to the control group will receive a saline placebo. The primary study outcome will be a
change in the Sequential Organ Failure Assessment (SOFA) score from baseline to three days
after the first dose of drug (dSOFA3). Secondary outcomes will include total vasopressor dose
in norepinephrine equivalents, 30-day and 1-year mortality, and serum AA levels.